A Phase 3 interventional study of Daratumumab and Lenalidomide in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 73 sites in 2 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.
Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 30th largest by enrollment, is one of 23 that started in 2019, is one of 24 in phase 3, and was the 61st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 84 · Phase 3 25 · Phase 4 4
First in 2008; this study’s year is marked. 23 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 132 interventional studies. Of the 55 that completed or were terminated, 28 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 132 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 39th largest by enrollment of the 100 interventional ones that give a count, is one of 7 that started in 2019, is one of 35 in phase 3, and was the 81st registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
19 of the studies testing daratumumab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06952478Phase 3CelltrionA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | 2027-03-08 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT06697483Peking University People's HospitalRisk Stratification and MRD-driven Maintenance for MM After ASCT | 2026-12-31 |
| NCT04991103University of Alabama at BirminghamMinimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | 2027-01-01 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 132 studies testing daratumumab in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation sequencing (NGS) at screening, following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 1800 milligram (mg) daratumumab by subcutaneous (SC) injection in combination with lenalidomide (orally) as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
Drug: Daratumumab · Drug: Lenalidomide
Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
Drug: Lenalidomide
Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
Also known as: DARZALEX
Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS)
Percentage of participants who achieved MRD negative (MRD conversion) status from baseline to 12 months after maintenance treatment was defined as percentage of participants who were MRD positive at baseline (randomization) and achieved MRD negative status (at 10\^-5) during the time period from randomization to 12 months plus 2 months window, but prior to progressive disease (PD) and subsequent anti-myeloma therapy.
Time frame: From randomization up to 12 months
Progression-free Survival (PFS)
Time frame: From randomization to either disease progression or death (up to 7.1 years)
Percentage of Participants Who Achieved Overall MRD (at 10^-5) Negativity Conversion From Baseline to End of Study Treatment Period
Time frame: From randomization up to 30 days after last dose of study treatment or disease progression or initiation of subsequent therapy, whichever occurs first (up to 3 years)
Percentage of Participants Who Achieved Durable (Greater Than or Equal to [>=] 12 Months) MRD Negative Status (10^-5)
Time frame: From randomization up to 30 days after last dose of study treatment or disease progression or initiation of subsequent therapy, whichever occurs first (up to 3 years)
Response Rates by International Myeloma Working Group (IMWG) 2016 Criteria
Time frame: From randomization up to 30 days after last dose of study treatment or disease progression or initiation of subsequent therapy, whichever occurs first (up to 3 years)
Overall Survival (OS)
Time frame: From randomization up to 7.1 years
Duration of Complete Response (CR)
Time frame: From date of initial documentation of CR or sCR up to first documented disease progression or death due to disease progression whichever occurs first (up to 7.1 years)
Health-related Quality of Life: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-C30 (EORTC QLQ-C30)
Time frame: From baseline (Cycle 1 Day 1) up to 7.1 years
Health-related Quality of Life: Change From Baseline in European Quality of Life Five Dimensions Questionnaire-5-level (EQ-5D-5L)
Time frame: From baseline (Cycle 1 Day 1) up to 7.1 years
Health-related Quality of Life: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Multiple Myeloma Module (EORTC QLQ-MY20)
Time frame: From baseline (Cycle 1 Day 1) up to 7.1 years
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: From Cycle 1 Day 1 up to 30 days after the last study treatment or day prior to start of subsequent antimyeloma therapy (up to 7.1 years)
| Milestone | Daratumumab + Lenalidomide | Lenalidomide |
|---|---|---|
| Started | 99 | 101 |
| Treated | 96 | 98 |
| Completed | 5 | 10 |
| Not completed | 94 | 91 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 11 |
| Withdrew: Ongoing | 84 | 73 |
| Withdrew: Randomized but not treated | 3 | 3 |
Percentage of participants who achieved MRD negative (MRD conversion) status from baseline to 12 months after maintenance treatment was defined as percentage of participants who were MRD positive at baseline (randomization) and achieved MRD negative status (at 10\^-5) during the time period from randomization to 12 months plus 2 months window, but prior to progressive disease (PD) and subsequent anti-myeloma therapy.
| percentage of participants | Daratumumab + Lenalidomide | Lenalidomide |
|---|---|---|
| Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) | 50.5 (40.3 to 60.7) | 18.8 (11.7 to 27.8) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over From Cycle 1 Day 1 up to 30 days after the last study treatment or day prior to start of subsequent antimyeloma therapy (up to 4.9 years). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daratumumab + Lenalidomide | 5/99 (5.1%) | 29/96 (30.2%) | 95/96 (99%) |
| Lenalidomide | 9/101 (8.9%) | 22/98 (22.4%) | 97/98 (99%) |
| Event | Daratumumab + Lenalidomide | Lenalidomide |
|---|---|---|
| PneumoniaInfections and infestations | 4/96 | 4/98 |
| PyrexiaGeneral disorders | 3/96 | 0/98 |
| AppendicitisInfections and infestations | 2/96 | 0/98 |
| DiverticulitisInfections and infestations | 2/96 | 0/98 |
| SepsisInfections and infestations | 2/96 | 1/98 |
| Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/96 | 0/98 |
| Cerebrovascular AccidentNervous system disorders | 2/96 | 0/98 |
| Acute Kidney InjuryRenal and urinary disorders | 2/96 | 1/98 |
| Covid-19 PneumoniaInfections and infestations | 1/96 | 2/98 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/96 | 2/98 |
| Event | Daratumumab + Lenalidomide | Lenalidomide |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 62/96 | 60/98 |
| DiarrhoeaGastrointestinal disorders | 59/96 | 54/98 |
| FatigueGeneral disorders | 44/96 | 46/98 |
| Upper Respiratory Tract InfectionInfections and infestations | 40/96 | 26/98 |
| CoughRespiratory, thoracic and mediastinal disorders | 37/96 | 36/98 |
| HypokalaemiaMetabolism and nutrition disorders | 33/96 | 36/98 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 32/96 | 36/98 |
| Back PainMusculoskeletal and connective tissue disorders | 31/96 | 20/98 |
| LeukopeniaBlood and lymphatic system disorders | 25/96 | 28/98 |
| Covid-19Infections and infestations | 27/96 | 26/98 |
| Age, Continuous(years) | Daratumumab + Lenalidomide | Lenalidomide | Total |
|---|---|---|---|
| Mean | 61.3 ± 8.12 | 60.8 ± 9.54 | 61 ± 8.84 |
| Sex: Female, Male(Participants) | Daratumumab + Lenalidomide | Lenalidomide | Total |
|---|---|---|---|
| Female | 38 | 43 | 81 |
| Male | 61 | 58 | 119 |
| Ethnicity (NIH/OMB)(Participants) | Daratumumab + Lenalidomide | Lenalidomide | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 6 | 15 |
| Not Hispanic or Latino | 81 | 89 | 170 |
| Unknown or Not Reported | 9 | 6 | 15 |
| Race/Ethnicity, Customized(Participants) | Daratumumab + Lenalidomide | Lenalidomide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 5 | 1 | 6 |
| Black or African American | 20 | 24 | 44 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 67 | 68 | 135 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Other | 4 | 4 | 8 |
| Region of Enrollment(Participants) | Daratumumab + Lenalidomide | Lenalidomide | Total |
|---|---|---|---|
| Canada | 2 | 0 | 2 |
| United States | 97 | 101 | 198 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Apr 2019 to primary completion in Apr 2024, 59 months.
Results were first posted in Apr 2025, 1 year after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 59 months is above that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →